Join to View Full Profile
5115 Centre AveHillman Cancer Center 2ND FLRPittsburgh, PA 15232
Phone+1 412-623-3398
Dr. Davar is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Diwakar Davar is an oncologist in Pittsburgh, PA and is affiliated with multiple hospitals in the area, including Hillman Cancer Center, UPMC Presbyterian Shadyside - Shadyside, UPMC Magee-Womens Hospital, and UPMC Presbyterian.
He received his medical degree from National University of Singapore and obtained a Masters from the University of Pittsburgh.
He specializes in hematologic oncology and is experienced in melanoma, cSCC, Merkel cell carcinoma and phase I trials.
Education & Training
- UPMC Medical EducationFellowship, Hematology and Medical Oncology, 2013 - 2016
- UPMC Medical EducationResidency, Internal Medicine, 2009 - 2012
- National University of Singapore FOMClass of 2005
Certifications & Licensure
- PA State Medical License 2009 - 2026
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Fecal Microbiota Transplant (FMT) in Melanoma Patients Start of enrollment: 2018 Mar 19
- CMP-001 in Combo With Nivolumab in Stage IIIB/C/D Melanoma Patients With Clinically Apparent Lymph Node Disease Start of enrollment: 2018 Aug 08
- Study of TLR9 Agonist Vidutolimod (CMP-001) in Combination with Nivolumab Vs. Nivolumab Start of enrollment: 2020 Sep 02
Publications & Presentations
PubMed
- There and back again: PD-L1 Positivity as a Biomarker for Immune Checkpoint Blockade in Urothelial Carcinoma.Arivarasan Karunamurthy, Diwakar Davar
Cancer Immunology Research. 2025-04-02 - Radiomic analysis of patient and interorgan heterogeneity in response to immunotherapies and BRAF-targeted therapy in metastatic melanoma.Alexandra G Tompkins, Zane N Gray, Rebekah E Dadey, Serafettin Zenkin, Nasim Batavani
Journal for Immunotherapy of Cancer. 2025-02-12 - Phase I trial of ATR inhibitor elimusertib with FOLFIRI in advanced or metastatic gastrointestinal malignancies (ETCTN 10406).Anuradha Krishnamurthy, Hong Wang, John C Rhee, Diwakar Davar, Ryan H Moy
Cancer Chemotherapy and Pharmacology. 2025-01-22
Authored Content
- Could Your Gut Microbes Hinder Your Cancer Treatment? A New First-in-Human Trial InvestigatesJuly 2018
- Could Your Gut Microbes Hinder Your Cancer Treatment? A New First-in-Human Trial InvestigatesJuly 2018
- Could Your Gut Microbes Hinder Your Cancer Treatment? A New First-in-Human Trial InvestigatesJuly 2018
- Could Your Gut Microbes Hinder Your Cancer Treatment? A New First-in-Human Trial InvestigatesJuly 2018
- Could Your Gut Microbes Hinder Your Cancer Treatment? A New First-in-Human Trial InvestigatesJuly 2018
- Could Your Gut Microbes Hinder Your Cancer Treatment? A New First-in-Human Trial InvestigatesJuly 2018
- Could Your Gut Microbes Hinder Your Cancer Treatment? A New First-in-Human Trial InvestigatesJuly 2018
- Could Your Gut Microbes Hinder Your Cancer Treatment? A New First-in-Human Trial InvestigatesJuly 2018
- Could Your Gut Microbes Hinder Your Cancer Treatment? A New First-in-Human Trial InvestigatesJuly 2018
- Join now to see all
Press Mentions
- Subcutaneous Nivolumab Reduces Burden of Melanoma Care, Expert SaysMarch 13th, 2025
- Liquid Biopsies Reliably Predict Immunotherapy Outcomes in Melanoma StudyMarch 10th, 2025
- New Drug Combo Shows Significant Promise in Advanced Melanoma TrialNovember 5th, 2024
- Join now to see all
Grant Support
- Proteogenomic studies to understand mechanisms and drivers of resistance to immunotherapiesFRED HUTCHINSON CANCER CENTER2022–2027
- Neoadjuvant Immunotherapy with Intratumoral CPG and PD-1 Blockade in MelanomaUNIVERSITY OF PITTSBURGH AT PITTSBURGH2021–2026
- Neoadjuvant Immunotherapy with Intratumoral CPG and PD-1 Blockade in MelanomaUNIVERSITY OF PITTSBURGH AT PITTSBURGH2021–2026
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
